Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Crinetics Pharmaceuticals (CRNX)
NASDAQ:CRNX
RESEARCH TOOLSreports
Holding CRNX?
Track your performance easily
CRNX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$35.24 - $62.53
Previous Close$48.5
Volume2.16M
Average Volume (3M)719.22K
Market Cap
$3.77B
Enterprise Value$3.69B
Total Cash (Recent Filing)$862.67M
Total Debt (Recent Filing)$52.54M
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Mar 18, 2025EPS Estimate
-$0.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.72
Shares Outstanding92,737,627
10 Day Avg. Volume498,108
30 Day Avg. Volume719,219
Standard Deviation0.15
R-Squared0.04
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)5.40
Price to Sales (P/S)4328.95
Price to Cash Flow (P/CF)-17.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.55K
Enterprise Value/Gross Profit918.92
Enterprise Value/Ebitda-13.12
Forecast
1Y Price Target
$74.42Price Target Upside83.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Crinetics Pharmaceuticals News
PremiumCompany Announcements
Crinetics Pharmaceuticals Advances Atumelnant After Successful Phase 2
PremiumCompany Announcements
Crinetics Pharmaceuticals Strengthens Leadership with New Appointment
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPaltusotine has demonstrated striking efficacy in clinical studies, showing it is on par with standard of care depot injections for acromegaly.
Product AdvantagePaltusotine offers a convenience advantage as a once-daily oral drug and can be used for both treatment-naïve patients and those switching from injectable somatostatin receptor ligands, which should ease access.
Regulatory MilestonesThe FDA acceptance of Paltusotine NDA and the high probability of success for paltusotine are positive indicators for Crinetics Pharma.
Bears Say
Clinical DataKey opinion leaders express the need for data from more patients before forming a complete opinion on atumelnant.
Financial PerformanceR&D expense and SG&A expense saw a 48% increase year-over-year, driven by personnel costs and manufacturing/development activities.
Future ExpensesManagement indicated that quarterly R&D and SG&A expenses are likely to increase further with the acromegaly launch.
---
Ownership Overview
1.76% Insiders
33.10% Mutual Funds
36.76% Other Institutional Investors
14.12% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRNX FAQ
What was Crinetics Pharmaceuticals’s price range in the past 12 months?
Crinetics Pharmaceuticals lowest stock price was $35.24 and its highest was $62.53 in the past 12 months.
What is Crinetics Pharmaceuticals’s market cap?
Currently, no data Available
When is Crinetics Pharmaceuticals’s upcoming earnings report date?
Crinetics Pharmaceuticals’s upcoming earnings report date is Mar 18, 2025 which is in 67 days.
How were Crinetics Pharmaceuticals’s earnings last quarter?
Crinetics Pharmaceuticals released its earnings results on Nov 12, 2024. The company reported -$0.96 earnings per share for the quarter, missing the consensus estimate of -$0.911 by -$0.049.
Is Crinetics Pharmaceuticals overvalued?
According to Wall Street analysts Crinetics Pharmaceuticals’s price is currently Undervalued.
Does Crinetics Pharmaceuticals pay dividends?
Crinetics Pharmaceuticals does not currently pay dividends.
What is Crinetics Pharmaceuticals’s EPS estimate?
Crinetics Pharmaceuticals’s EPS estimate is -$0.89.
How many shares outstanding does Crinetics Pharmaceuticals have?
Crinetics Pharmaceuticals has 92,737,625 shares outstanding.
What happened to Crinetics Pharmaceuticals’s price movement after its last earnings report?
Crinetics Pharmaceuticals reported an EPS of -$0.96 in its last earnings report, missing expectations of -$0.911. Following the earnings report the stock price went up 0.238%.
Which hedge fund is a major shareholder of Crinetics Pharmaceuticals?
Among the largest hedge funds holding Crinetics Pharmaceuticals’s share is Driehaus Capital Management LLC. It holds Crinetics Pharmaceuticals’s shares valued at 301M.
---
Crinetics Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$74.42 (83.17% Upside)
$74.42 (83.17% Upside)
Blogger Sentiment
Bullish
CRNX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 279.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.90%
12-Months-Change
Fundamentals
Return on Equity
-40.26%
Trailing 12-Months
Asset Growth
46.11%
Trailing 12-Months
Company Description
Crinetics Pharmaceuticals
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. It is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.
---
CRNX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented several positive developments including the NDA submission for paltusotine, a strong financial position post-equity offering, and advancements in their drug pipeline and global expansion. However, the financial results showed increased expenses and a higher net loss with no current revenue. Despite these financial challenges, the strategic advancements and promising pipeline provide an optimistic outlook.Read More>---
CRNX Stock 12 Month Forecast
Average Price Target
$74.42
▲(83.17% Upside)
Technical Analysis
Arcutis Biotherapeutics
―
Blueprint Medicines
―
Ultragenyx Pharmaceutical
―
Fate Therapeutics
―
Best Analysts Covering CRNX
1 Year
1 Year Success Rate
11/13 ratings generated profit
1 Year Average Return
+71.95%
reiterated a buy rating 2 months ago
Copying Brian Skorney's trades and holding each position for 1 Year would result in 84.62% of your transactions generating a profit, with an average return of +71.95% per trade.
---